IGF::OT::IGF TOPIC 338 PHASE I SBIR PREDICTIVE BIOMARKERS OF ADVERSE REACTIONS TO PROSTATE CANCER RADIOTHERAPY
IGF::OT::IGF TOPIC 338 PHASE I SBIR PREDICTIVE BIOMARKERS OF ADVERSE REACTIONS TO PROSTATE CANCER RADIOTHERAPY
批准号:
9150853
负责人:
ELIZABETH PETERSON ROTH
金额:
$27.12万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-09-22 至 2016-06-21
关键词:
Adverse effectsAdverse reactionsBiological AssayBiological MarkersCancer PatientClinicalGoalsInjuryLate EffectsMalignant neoplasm of prostateMorbidity - disease ratePerformancePhaseRadiation ToleranceRadiation therapyRiskSingle Nucleotide PolymorphismSmall Business Innovation Research Grantbasecancer radiation therapycohortcostdesignnovelrectalurinary
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The overall objective of this project is to identify novel biomarkers of radio-sensitivity that will identify subsets of prostate cancer patients for which radiotherapy should be contraindicated. These novel biomarkers will subsequently be packaged in a robust, validated, sensitive and specific single nucleotide polymorphism (SNP)-based assay practical for use in the clinical setting. This assay will be capable of predicting the risk of developing adverse effects – principally urinary morbidity and rectal injury – resulting from radiotherapy treatment of prostate cancer. Through previous studies we have identified SNPs in multiple cohorts that are strongly associated with adverse effects resulting from radiotherapy. The goal of the current project is to validate these SNPs and discover new SNPs using multiple, independent cohorts and to initiate design of a multiplex assay to detect predictive SNPs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金